Polyphenols, Gut Inflammation, and the Cardiometabolic Gap

Polyphenol-rich foods appear to improve parts of the gut environment in adults with excess weight. They can shift microbial composition and lower circulating lipopolysaccharide (LPS), a marker often used to study metabolic endotoxemia. A small crossover trial also found lower fecal calprotectin, a marker of intestinal inflammation. What remains unproven is the leap many wellness claims make next: that these gut-level changes reduce cardiovascular events, reverse biological aging, or reliably improve cardiometabolic risk.

The most useful way to read this evidence is as a pathway with several gates. Diet changes the microbial ecosystem; microbial activity may affect short-chain fatty acids, gut-barrier function, and inflammatory markers; those changes may or may not reach clinically meaningful cardiometabolic outcomes. The first steps have human trial support. The last step still needs longer, better-stratified trials.

What the highest-level evidence actually found

A 2025 systematic review and meta-analysis by González-Gómez et al. combined 13 randomized controlled trials in adults with a BMI of at least 25 kg/m². Across those trials, polyphenol-rich interventions reduced circulating LPS and altered gut microbiota composition alongside inflammatory and oxidative-stress markers. The review identified Bifidobacterium species and Akkermansia muciniphila as recurring responders across trials.

That is meaningful evidence that polyphenol-rich dietary interventions can affect gut-related biomarkers in overweight and obese adults. It does not establish a universal microbiome signature, a proven optimal dose, or a cardiovascular treatment effect. Different foods deliver different polyphenols, usually alongside different amounts of fiber, fat, and other bioactive compounds. The trials also differed in duration and baseline health.

The publication materials available for the LPS analysis do not report the pooled effect estimate, confidence interval, heterogeneity statistic, or publication-bias assessment for that endpoint. So the direction of the meta-analytic finding is known, but its exact size and resilience to small-study or publication bias cannot be judged here. A meta-analysis is only as informative as the trials and reporting underneath it.

A small trial measured the intestine more directly

The SINFONI crossover randomized trial offers a closer look at the proposed mechanism. Thirty people at cardiometabolic risk followed a multifunctional dietary cereal intervention for two months and were compared with an inert control. The intervention reduced fecal calprotectin versus control (p=0.007), fasting serum LPS (p<0.05), and serum branched-chain amino acids, or BCAAs (p<0.05).

Calprotectin matters because it is a direct stool marker of intestinal inflammation, rather than a broad blood marker with many possible sources. In the same trial, four taxa increased relative to control: Bacteroides ovatus, Bacteroides uniformis, Akkermansia butyriciproducens, and unclassified Christensenellaceae CAG-74. Those changes are interesting leads, not a validated microbial prescription.

The trial has important limits. With 30 participants, it was small for microbiome-composition endpoints, where researchers test many taxa at once. The available report does not provide false-discovery-rate-adjusted thresholds for those taxon-level results. More importantly, the cereal intervention was multifunctional. It cannot separate effects of polyphenols from fiber or other dietary components. The LPS and calprotectin findings belong to the whole intervention, not to polyphenols alone.

Fiber is a serious alternative explanation

Fiber is not background scenery in this story. In the randomized LIBRE trial, short-chain fatty acids mediated favorable effects of a Mediterranean diet on intestinal barrier integrity. Short-chain fatty acids arise largely when gut microbes ferment dietary fiber. That analysis supports a plausible diet-to-microbe-to-barrier pathway, but mediation analysis does not prove that one nutrient class alone caused every downstream effect.

Two 2025 evidence reviews reinforce the point. A meta-analysis of probiotics, prebiotics, and synbiotics reported improvements in intestinal-permeability markers, while a systematic review of prebiotic fibers, probiotics, and synbiotics found evidence that prebiotic fiber can influence gut-barrier function and immune measures. This makes it impossible to credit the SINFONI findings to polyphenols alone.

That does not make polyphenols irrelevant. A defined-polyphenol test helps support their independent biological activity: a randomized, double-blind, placebo-controlled pomegranate-extract trial found changes in gut microbiome composition and short-chain-fatty-acid profiles. But changing a microbial profile or metabolite profile is still a surrogate outcome. It is not proof of fewer heart attacks, less diabetes, or longer life.

The cardiometabolic bridge remains incomplete

The SINFONI trial did not report improved systemic inflammation markers or cardiometabolic endpoints during its two-month intervention. That null result deserves equal billing with the favorable gut markers. Two months may be too short, 30 participants may be too few, or intestinal changes may simply fail to produce large systemic changes in many people. The current evidence cannot distinguish among those explanations.

A Green-Mediterranean diet randomized trial linked cardiometabolic benefits with gut-microbiome modifications. It supports the broader idea that whole dietary patterns can improve cardiometabolic health while altering the microbiome. It does not prove that a particular bacterium, polyphenol, or LPS change caused the benefit. Whole diets move many variables at once, including fiber intake, body weight, food displacement, and adherence habits.

Your microbiome may determine whether a polyphenol becomes active

Some polyphenols require bacterial conversion before the body encounters their better-studied downstream metabolites. Urolithin A can arise from ellagitannin-rich foods such as pomegranate, and equol can arise from soy isoflavones, but production depends on pre-existing microbial capacity. A 2023 metabotype study by Iglesias-Aguirre et al. found distinct microbial networks associated with the ability to metabolize resveratrol, daidzein, and ellagic acid precursors; some people lacked the relevant metabolite-producing capacity.

This is more than a laboratory curiosity. In overweight or obese adults with mild dyslipidemia, a 2024 clinical study of pomegranate polyphenols found that urolithin A metabotype determined whether bile-acid and cholesterol-metabolism shifts occurred. A 2026 randomized placebo-controlled crossover trial in postmenopausal women likewise reported that effects on the atherogenic biomarker TMAO varied by urolithin A and equol metabotype.

These findings make a practical case for modest expectations and individualized interpretation. They do not yet justify routine microbiome sequencing to select supplements. No trial here establishes a validated test threshold, shows that changing a metabotype improves clinical outcomes, or proves that high-dose ellagitannin or isoflavone supplements benefit producers.

What to do with this now

Build meals around polyphenol-rich plant foods and fiber because the dietary pattern is sensible and the gut evidence is credible: berries, legumes, nuts, cocoa, tea, extra-virgin olive oil, whole grains, and vegetables fit that description. Treat them as food, not as a substitute for blood-pressure control, lipid treatment, exercise, sleep, or evidence-based care.

Do not buy a heart-health promise based on a lower LPS value or a prettier microbiome chart. The controlled evidence supports gut biomarker changes in adults with BMI at least 25 kg/m²; it does not yet show that those changes produce cardiovascular benefit within short trial windows. The gut may be the gatekeeper, but the clinical destination is still down the road.